How can specialists know that a drug is effective and has no side effects? With this question started the debate of the Television Española programme ‘Para Todos la 2’ of Monday 6th, dedicated to clinical trials.Xavier Molina, head of clinical research and clinical trials promotion at Vall d’Hebron Research Institute (VHIR), talked about the new spaces at Vall d'Hebron dedicated exclusively to clinical trials, which will be working in a few weeks. A space of more than 900m2 dedicated to the clinical research that companies are nowadays looking for “in order to optimize resources, pharmaceutical labs are concentrating clinical research in leading centers like Vall d’Hebron where the quality of clinical trials is adapted to the demands of the regulator”, Molina assured. In the debate also participated Dr. Xavier Luria, independent consultant for the development and regulation of new drugs, and Dr. José Antonio Sacristán, medical director of the Spanish division of Lilly Labs. The situation of clinical trials in Spain, the different phases that a drug must follow before arriving to the market and the protection of patients, were other questions put on the table during the debate.Before the discussion, the programme broadcasted a report about the new floor dedicated to clinical trials at VHIR, with the participation of Imma Fuentes, head of the Clinical Research Support Unit, and the obstetrics Elisa Llurba, who explained a Spanish public clinical trial that is being coordinated at VHIR.